These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37978179)

  • 1. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis.
    Zhang H; Quadeer AA; McKay MR
    Nat Commun; 2023 Nov; 14(1):7457. PubMed ID: 37978179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
    Sorbo MC; Cento V; Di Maio VC; Howe AYM; Garcia F; Perno CF; Ceccherini-Silberstein F
    Drug Resist Updat; 2018 Mar; 37():17-39. PubMed ID: 29525636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
    Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
    Svarovskaia ES; Martin R; McHutchison JG; Miller MD; Mo H
    J Clin Microbiol; 2012 Oct; 50(10):3267-74. PubMed ID: 22837328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
    Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
    Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.
    Abe H; Hayes CN; Hiraga N; Imamura M; Tsuge M; Miki D; Takahashi S; Ochi H; Chayama K
    Am J Gastroenterol; 2013 Sep; 108(9):1464-72. PubMed ID: 23896953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness.
    Guo M; Lu J; Gan T; Xiang X; Xu Y; Xie Q; Zhong J
    Antiviral Res; 2019 Nov; 171():104612. PubMed ID: 31542377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.
    Welsch C
    Drug Discov Today Technol; 2014 Mar; 11():19-25. PubMed ID: 24847649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of RASs /RVs in the Current Management of HCV.
    Malandris K; Kalopitas G; Theocharidou E; Germanidis G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
    Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
    Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    Fahnøe U; Pedersen MS; Sølund C; Ernst A; Krarup HB; Røge BT; Christensen PB; Laursen AL; Gerstoft J; Thielsen P; Madsen LG; Pedersen AG; Schønning K; Weis N; Bukh J
    J Viral Hepat; 2021 Feb; 28(2):302-316. PubMed ID: 33131178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing.
    Nakamura F; Takeda H; Ueda Y; Takai A; Takahashi K; Eso Y; Arasawa S; Iguchi E; Shimizu T; Mishima M; Kumagai K; Yamashita T; Uemoto S; Kato N; Marusawa H; Sekine A; Seno H
    Sci Rep; 2022 Apr; 12(1):7083. PubMed ID: 35490163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients.
    Baesi K; Velayati AA; Ashtiani MF; Fakhredini K; Banifazl M; Larijani MS; Basimi P; Ramezani A
    Curr HIV Res; 2021; 19(5):391-397. PubMed ID: 34238162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
    Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
    BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.